McKesson raises FY2027 adjusted EPS guidance after 20% Q1 adjusted EPS gain
McKesson reported first-quarter fiscal 2027 revenue of $105.4 billion, up 8%, and adjusted earnings per diluted share of $9.93, up 20%, and raised its full-year adjusted EPS guidance to $44.20 to $45.00. GAAP EPS fell 18% to $5.15, mainly because of a $293 million redemption value adjustment tied to the Medical-Surgical Solutions minority stake sold to Apollo Funds, so shareholders face a mixed picture between the higher adjusted results and the lower GAAP profit.
Key points
- Revenue of $105.4 billion rose 8% from $97.8 billion a year earlier.
- GAAP EPS was $5.15 versus $6.25, a decrease of $1.10, primarily due to a $293 million redemption value adjustment.
- Adjusted EPS was $9.93 versus $8.26, an increase of 20%.
- Full-year fiscal 2027 adjusted EPS guidance was raised to $44.20 to $45.00 from $43.80 to $44.60; the quarterly dividend was raised 15% to $0.94 per share.
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.